Telix Pharmaceuticals Limited (TLPPF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は North Melbourne, VIC, オーストラリア. 現CEOは Christian Behrenbruch.
TLPPF を有する IPO日 2019-07-25, 415 名の正社員, に上場 Other OTC, 時価総額 $3.56B.
Telix Pharmaceuticals Limited is a radiopharmaceutical company developing molecularly targeted radiation products for cancer and rare diseases across Australia, Belgium, Japan, Switzerland, and the United States. The company's pipeline includes diagnostic and therapeutic candidates addressing significant unmet medical needs, with lead programs in metastatic castrate-resistant prostate cancer, renal cancer, glioblastoma, and bone marrow conditioning. Key assets in late-stage development include TLX591-CDx and TLX591 for prostate cancer, TLX250-CDx for kidney cancer, and TLX101-CDx for brain cancer, complemented by earlier-stage programs such as TLX592 for targeted alpha therapy and TLX599-CDx for prostate cancer imaging. Telix has established strategic partnerships with China Grand Pharmaceutical and Healthcare Holdings Limited, Mauna Kea Technologies, and Lightpoint Medical to advance its molecular imaging and therapeutic platform. Founded in 2015 and headquartered in North Melbourne, Australia, the company is focused on translating its targeted radiation technology into clinical solutions for oncology and rare disease indications.
